Treatment of acute hepatitis C with interferon alfa-2b

New England Journal of Medicine

Volumn 345, Issue 20, 2001, Pages 1452-1457

  Jaeckel, Elmar ^a   Cornberg, Markus ^b   Wedemeyer, Heiner ^a   Santantonio, Teresa ^c   Mayer, Julika ^a   Zankel, Myrga ^d   Pastore, Giuseppe ^a   Dietrich, Manfred ^a   Trautwein, Christian ^a   Manns, Michael P ^a,e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BARI   (Italy)

^c Essex Pharma   (Germany)

^d BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^e Department of Gastroenterology and Hepatology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ACUTE HEPATITIS; ACUTE PHASE RESPONSE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DISEASE TRANSMISSION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GERMANY; HEPATITIS C; HUMAN; INCUBATION TIME; INTRAVENOUS DRUG ABUSE; MALE; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SIDE EFFECT;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0035892032     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011232     Document Type: Article

References (46)

1. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
2. Liver transplantation for chronic viral hepatitis
3. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
4. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome
5. Natural history of liver fibrosis progression in patients with chronic hepatitis C
6. Treatment of acute hepatitis C with interferon α-2b prevents chronicity
7. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
8. Natural beta interferon in acute type-C hepatitis patients: A randomized controlled trial
9. Acute sporadic non-A, non-B hepatitis in northeastern Brazil: Etiology and natural history
10. Role of the specific T-cell response for clearance and control of hepatitis C virus
11. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study
12. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomized trial
13. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
14. Immune control of HIV-1 after early treatment of acute infection
15. Vigorous HIV-1-specific CD4+ T cell responses associated with control ofviremia
16. Immunology taught by viruses
17. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells
18. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection
19. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
20. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
21. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
22. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C
23. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
24. Analysis of successful immune responses in persons infected with hepatitis C virus
25. Interaction between the hepatitis C virus and the immune system
26. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
27. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
28. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
29. EASL International Consensus Conference on hepatitis C: Paris, 26-28, February 1999, consensus statement
30. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C
31. Interferon-alpha in acute posttransfusion hepatitis C: A randomized, controlled trial
32. 2b in patients with acute transfusion-associated hepatitis C
33. Outcome of acute hepatitis C and role of interferon alpha therapy
34. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study
35. Resolution of acute hepatitis C after therapy with natural beta interferon
36. Interferon therapy for acute post-transfusion non-A, non-B hepatitis: Response with respect to anti-hepatitis C virus antibody status
37. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis
38. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha
39. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: A pilot study
40. A trial of interferon beta la (IFN β1a) for 4 weeks for therapy of acute hepatitis C
41. High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for acute hepatitis C
42. Acute hepatitis C
43. A cohort study of acute hepatitis C virus (HVC) infection: Natural course and outcome
44. Natural history of hepatitis C
45. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening
46. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia